All In Biotech

Drug Trial Radar · NCT06464939

Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity

A Randomized, Double-blinded, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Three Topical Applications of KH001 in Providing Long-term Relief From Dentin Hypersensitivity

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Oct 8, 2024

Primary completion

Dec 22, 2025

Study completion Dec 22, 2025

Sponsor

Lead sponsor
HysensBio Co., LtdIndustry
Sponsor type
Industry
Collaborators
The Forsyth Institute
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of KH001 in subjects with dentin hypersensitivity.

Conditions

  • Dentin Hypersensitivity

Interventions

  • KH001Drug

    Application of KH001 over a 1 or 2-week period

  • PlaceboDrug

    Applications of water for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Schiff sensitivity scoreTime frame: Baseline and Week 5

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • ADA Forsyth

    Cambridge, Massachusetts

  • Forsyth Institute

    Cambridge, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.